Query Molecule Profile Results
Molecule: 1
Click HERE to jump to Bioactive Database HitsClick HERE to jump to Toxicity Database Hits
Click HERE to jump to Available Compound Database Hits
Click HERE to jump to the ADME Profile
Bioactive Database Search Results
| Bioactive | TanSim | Source | ActClass | Action | LitRef | Annotations |
 |
1.000 | CBNK2005 | bioactive | 5HT Antagonist (2) Known Drug - Indications/Usage: Analgesic, antipyretic (1) |
Beretta, C. 1965 |
CBNKID: 910 MOLNAME: metergoline SOLUBILITY: DMSO CAS: 17692-51-2 VENDOR: MicroSource 300565 NINDS 300565 |
 |
1.000 | CMCR2004 | Antipyretic | Antipyretic | (2) Camerino et al., U.S. Pat. 3 238 211 (1966). | ChemicalName: METERGOLINE LogP: 4.33 CommericalSource: Farmitalia, Italy pKa: NA CAS: 17692-51-2 |
 |
0.485 | CMCR2004 | Dopamine receptor antagonist | Dopamine receptor antagonist | (1) Life Sci., 1981, 29, 2227. | ChemicalName: MESULERGINE LogP: 1.53 CommericalSource: Sandoz, Switz. pKa: NA CAS: 64795-35-3 |
 |
0.455 | CMCR2004 | Antispasmodic | Antispasmodic | NULL | ChemicalName: METOQUIZINE LogP: 3.19 CommericalSource: Lilly pKa: NA CAS: 7125-67-9 |
 |
1.000 | LPAC2004 | Serotonin Antagonist | 5-HT1/5-HT2 Serotonin receptor antagonist; analgesic; antipyretic | NA | MOLNAME: Metergoline CATNUM: M 3668 |
 |
0.568 | LPAC2004 | Dopamine Agonist | Dopaminergic receptor agonist exhibiting antiparkinsonian activity; 5-HT2C serotonin receptor antagonist | NA | MOLNAME: Mesulergine hydrochloride CATNUM: M-153 |
 |
1.000 | MCSR2004 | Bioactive Standard | Therap cat: analgesic, antipyretic | NULL | MOLNAME: METERGOLINE SN: 538977391 ID: 00300565 |
 |
1.000 | MCSRBASC | Bioactive | analgesic, antipyretic | NULL | MOLNAME: METERGOLINE ID: 00300565 CAS: 17692-51-2 |
 |
1.000 | MDDR2004 | Antimigraine | NULL | NULL | ChemicalName: METERGOLINE TestingPhase: Launched CommericalSource: Pharmacia PatentNumber: NA CAS: 17692-51-2 |
 |
0.430 | MDDR2004 | Cognition Disorders, Agent for | NULL | NULL | ChemicalName: 142896 TestingPhase: Biological Testing CommericalSource: Pfizer PatentNumber: EP 251652;19880107 JP 88022577;19880130 CAS: NA |
 |
1.000 | TCRS2005 | Serotonergic | 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7 | NA | MOLNAME: Metergoline phenylmethyl ester CATNUM: 0590 |
Toxicity Database Search Results
| ToxicMol | TanSim | Source | ActClass | Action | LitRef | Annotations |
| NO HITS | ||||||
Available Compounds Database Search
| Available | SimTan | Source | Category | SuppID | PlateID | Well | Annotations |
 |
1.000 | BASC | ScreenEntirePlates | AB-00129962:BATCH-01 | 01821MS | A04 | COMPANY: Bay Area Screening Center INFO: Microsource 96 well plate |
 |
1.000 | MCSR | CherryPickable | 00300565 | NA | NA | COMPANY: Microsource MOLNAME: METERGOLINE SN: 538977391 |
 |
0.607 | SGSA | CherryPickable | R736643 | NA | NA | COMPANY: Sigma SALOR COLLECTION: Screening Set MW: 270.37 PURITY: 95 SHIPWIN: 7 |
 |
0.515 | SGSA | CherryPickable | R948470 | NA | NA | COMPANY: Sigma SALOR COLLECTION: Screening Set MW: 368.52 PURITY: 95 SHIPWIN: 7 |
 |
0.414 | SGSA | CherryPickable | R948640 | NA | NA | COMPANY: Sigma SALOR COLLECTION: Screening Set MW: 382.55 PURITY: 95 SHIPWIN: 7 |
 |
1.000 | TCRS | CherryPickable | ST056348 | NA | NA | COMPANY: Tocris COLLECTION: Screening Set MW: 403.52 PURITY: 90 SHIPWIN: 10 |
 |
1.000 | TCRS | CherryPickable | 0590 | NA | NA | COMPANY: Tocris COLLECTION: Screening Set MOLNAME: Metergoline phenylmethyl ester ACTIVITY: CherryPickable SOLVENT: DMSO |
ADME Profiler (v1.5) Results
| Probe | ID | ADME Score Reflects the weighted contribution of all the ADME models except BBB; a molecule with a low score is more likely to be orally bioavailable and less toxic | Lip. Viols. | REOS Flags | Int. Perm. Intestinal Permeability Model | ADMET Aq. Sol. | TETKO Aq. Sol. | BBB Model Blood Brain Barrier Penetration Model | Plasma Protein Binding | CYP 2D6 Inh. | Hep Tox | Oprea Viols. | Ghose Viols. | S.F. Flags Suspect Feature Flag |
 |
1 | 1.0 | NONE | NONE |
Good Passive Int. Perm. |
Low Solubility:(LogSw =-5.83 mol/L) |
Very Low Solubility:(LogSw =-6.21 mol/L) |
High BBB Penetration: (LogBBB =0.40) |
Moderate Plasma Protein Binding (>=90%) |
Unlikely CYP2D6 Inh: (P=0.45) |
Unlikely Hep. Toxin: (P=0.25) |
Failed Oprea # Rings (Count = 5)Failed 1 of 4 Rules |
NONE | NONE |
ADME Model Information
- Lipinski Violations: (1) MW > 500, (2) Num_H_Accs > 10, (3) Num_H_Donors > 5, (4) AlogP > 6; (ref: Lipinski et al, Advanced Drug Delivery Reviews 46, 2001, 3–26)
- REOS Features: Structures deemed inappropriate for HTS; (ref: Rishton, Drug Discovery Today, 2, 9, Sept 1997; M. Hann et al. J. Chem. Inf. Comput. Sci. 39, 1999, 897–902.; Walters et al, Advanced Drug Delivery Reviews 54, 2002, 255–271; consultations with Medicinal Chemists)
- Intestinal Permeability Model (%Abs): (a) 0 = Very Low Absorption; (b) 1 = Low Absorption; (c) 2 = Moderately absorbed; (d) 3 = Well absorbed (>90%); (ref: Egan et al, J. Med. Chem. 2000,43, 3867–3877; Egan, W.J., Lauri, G., Adv. Drug Del. Rev., 54, 273, 2001)
- ADMET Solubility Model (Log mol/L): (a) 0 = Extremely Low Solubility (<-8.0); (b) 1 = Very Low Solubility (-8.0 – -6.0); (c) 2 = Low Solubility (-6.0 – -4.0); (d) 3 = Moderate Solubility (-4.0 – -2.0); (e) 4 = Optimal Solubility (-2.0 – 0.0); (f) 5 = Very Soluble (>0.0); (g) 6 = Undefined; (ref: Cheng, A. and Merz, Jr., K. "Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships," J. Med. Chem. 2003, 46, 3572–3580).
- TETKO Solubility Model (Log mol/L): (a) 0 = Extremely Low Solubility (<-8.0); (b) 1 = Very Low Solubility (-8.0 – -6.0); (c) 2 = Low Solubility (-6.0 – -4.0); (d) 3 = Moderate Solubility (-4.0 – -2.0), (e) 4 = Optimal Solubility (-2.0 – 0.0); (f) 5 = Very Soluble (>0.0); (ref: Scitegic's Pipeline Pilot model based on Tetko et al.,J Chem Inf. Comput. Sci, 2001, 41, 1488–1493, "Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices)
- Blood Brain Barrier (BBB) Permation: (a) 0 = Undefined; (b) 1 = Outside Confidence Range; (c) 2 = Low Permation (Blood:Brain > 0.3); (d) 3 = Medium Permation (Blood:Brain 0.3 > 1:1); (e) 4 = High Permeation Brain:Blood 1:1 > 5:1); (f) 5 = Very High Permation (Blood:Brain > 5:1); (ref: Accelrys Proprietary model);
- Plasma Protein Binding (PPB): (a) 0 = <90%; (b) 1 = >=90%, (c) 2 = >95%; (ref: Dixon, S.L. and Merz, K.M.M., Jr. "One-Dimensional Molecular Representations and Similarity Calculations: Methodology and Validation," J. Med. Chem., 2001, 44, 3795–3809.)
- CYP 2D6 Inhibition: (a) 0 = Non-Inhibitor; (b) 1 = Inhibitor; (ref: Dixon, S.L., Villar, H.O., J. Comput. Aided Mol. Design, 13, 533 (1999).; Susnow, R.G., Dixon, SL, "Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition," J. Chem. Inf. Comput. Sci., 2003, 43, 1308–1315)
- Hepatotoxicity: (a) 0 = Not Toxic; (b) 1 = Toxic; (ref: Dixon, SL; Villar, H.O., J. Comput. Aided Mol. Design, 13, 533 (1999); Cheng, A. and Dixon, SL In silico models for the prediction of dose-dependent human hepatotoxicity, J. Comput. Aided Mol. Design, 17, 811–823. (2003));
- Ghose Violations: (1) -0.4 <= AlogP <= 5.6, (2) 160 <= MW <= 480, (3) 40 <= MR <= 130, (4) 20 <= Num_Atoms <= 70; (ref: A.K. Ghose et al, J. Comb. Chem. 1, 1999, 55–67)
- Oprea Violations: (1) Num_H_Donors > 2, (2) 2 <= Num_H_Accs <= 9, (3) 2 <= Num_RBs <= 8, (4) 1 <= Num_Rings <= 4; (ref: Oprea, Journal of Computer-Aided Molecular Design, 14: 251–264, 2000)
- Suspect Substructure Violations: Compounds gleamed from medicinal chemistry literature that are known to be problematic for developing drug candidates